MCID: TRY001
MIFTS: 55

Trypanosomiasis

Categories: Infectious diseases

Aliases & Classifications for Trypanosomiasis

MalaCards integrated aliases for Trypanosomiasis:

Name: Trypanosomiasis 12 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10113
ICD10 32 B57.2
ICD9CM 34 086 086.9
MeSH 41 D014352
UMLS 69 C0041227

Summaries for Trypanosomiasis

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans.

MalaCards based summary : Trypanosomiasis is related to sleeping sickness and chagas disease. An important gene associated with Trypanosomiasis is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Carvedilol and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and brain, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 72 Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic... more...

Related Diseases for Trypanosomiasis

Diseases related to Trypanosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 383)
# Related Disease Score Top Affiliating Genes
1 sleeping sickness 32.7 AMD1 APOL1 HP HPR IL10 IL6
2 chagas disease 31.4 CALR CCL2 CCL3 CXCL8 IFNG IL10
3 leishmaniasis 30.7 IFNG IL10 IL1B IL4 TLR9 TNF
4 endomyocardial fibrosis 30.2 IL10 IL4 TNF
5 mycobacterium tuberculosis 1 30.2 IFNG IL10 IL4 TLR9 TNF
6 parasitic helminthiasis infectious disease 30.0 IL10 IL4 TLR9 TNF
7 cutaneous leishmaniasis 29.8 IFNG IL10 IL4 TLR9 TNF
8 uveitis 29.8 CCL2 IFNG IL10 IL4 TNF
9 toxoplasmosis 29.8 IFNG IL10 IL1B IL4 IL6 TLR9
10 onchocerciasis 29.4 CALR IL2 IL4
11 filariasis 29.2 ALB IFNG IL10 IL2 IL6 TLR9
12 brucellosis 29.0 CXCL8 IFNG IL10 IL2 IL4 IL6
13 schistosomiasis 28.8 ALB CCL3 IFNG IL10 IL2 IL4
14 malaria 26.8 ALB AMD1 CCL2 CCL3 CXCL8 HP
15 trypanosomiasis, human east-african 12.2
16 trypanosomiasis, human west-african 11.9
17 eastern equine encephalitis 10.9
18 punctate inner choroidopathy 10.7 IL10 TNF
19 scorpion envenomation 10.6 IL6 TNF
20 polyposis, gastric 10.6 IL1B TNF
21 multicentric castleman disease 10.6 IFNG IL10 IL6
22 eye lymphoma 10.6 IL10 IL6 TLR9
23 staphylococcal toxic shock syndrome 10.6 IFNG IL1B TNF
24 hand, foot and mouth disease 10.6 IFNG IL10 IL6
25 spotted fever 10.6 IFNG IL10 TNF
26 trachoma 10.6 IDO1 IL10 TNF
27 post-transplant lymphoproliferative disease 10.6 IL10 IL6 TNF
28 acute transverse myelitis 10.6 CXCL8 IL10 IL6
29 ascaris lumbricoides infection 10.6 IFNG IL1B IL6
30 laryngitis 10.6 IL1B IL6 TNF
31 acute vascular insufficiency of intestine 10.6 IL1B IL6 TNF
32 poems syndrome 10.6 IL1B IL6 TNF
33 osteosclerotic myeloma 10.6 IL1B IL6 TNF
34 scrub typhus 10.6 IL10 IL1B TNF
35 radiculopathy 10.5 CCL2 IL10 IL6
36 primary peritoneal carcinoma 10.5 CXCL8 IFNG IL10
37 ischemic heart disease 10.5 CCL2 IL6 TNF
38 recurrent corneal erosion 10.5 CXCL8 IL1B IL6
39 louse-borne relapsing fever 10.5 CXCL8 IL6 TNF
40 bagassosis 10.5 CXCL8 IL1B IL6
41 joint disorders 10.5 IL1B IL6 TNF
42 adult-onset still's disease 10.5 IL1B IL6 TNF
43 ileitis 10.5 IL6 TLR9 TNF
44 denture stomatitis 10.5 CCL2 CXCL8 IL6
45 dental pulp disease 10.5 CXCL8 IL1B TNF
46 chikungunya 10.5 IL1B IL6 TNF
47 post-thrombotic syndrome 10.5 CCL2 IL6 TLR9
48 vaginal disease 10.5 CXCL8 IL1B IL6
49 vaginitis 10.5 CXCL8 IL1B IL6
50 fasciitis 10.5 CXCL8 IL6 TNF

Graphical network of the top 20 diseases related to Trypanosomiasis:



Diseases related to Trypanosomiasis

Symptoms & Phenotypes for Trypanosomiasis

MGI Mouse Phenotypes related to Trypanosomiasis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ALB CALR HP IDO1 IFNG IL10
2 homeostasis/metabolism MP:0005376 10.13 ALB CALR HP IDO1 IFNG IL10
3 hematopoietic system MP:0005397 10.11 HP IDO1 IFNG IL10 IL1B IL2
4 digestive/alimentary MP:0005381 10.01 IL2 IL4 IL6 TLR9 TNF ALB
5 immune system MP:0005387 10 IL4 IL6 TLR9 TNF CCL2 HP
6 mortality/aging MP:0010768 9.77 ALB CALR HP IFNG IL10 IL1B
7 liver/biliary system MP:0005370 9.76 ALB HP IFNG IL10 IL2 IL4
8 neoplasm MP:0002006 9.23 IFNG IL10 IL1B IL2 IL6 TNF

Drugs & Therapeutics for Trypanosomiasis

Drugs for Trypanosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Warfarin Approved Phase 4 81-81-2 54678486 6691
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 70-26-8, 3184-13-2 6262
7 Nifurtimox Investigational Phase 4,Phase 3,Phase 2,Phase 1 23256-30-6
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Benzonidazole Phase 4,Phase 3,Phase 2
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
13 Adrenergic Agents Phase 4,Phase 3
14 Adrenergic alpha-1 Receptor Antagonists Phase 4
15 Adrenergic alpha-Antagonists Phase 4
16 Adrenergic Antagonists Phase 4,Phase 3
17 Adrenergic beta-Antagonists Phase 4,Phase 3
18 Angiotensin-Converting Enzyme Inhibitors Phase 4
19 Antihypertensive Agents Phase 4,Phase 3
20 HIV Protease Inhibitors Phase 4
21 Natriuretic Peptide, Brain Phase 4
22 Neurotransmitter Agents Phase 4,Phase 3
23
protease inhibitors Phase 4
24 Vasodilator Agents Phase 4,Phase 3
25 Anticoagulants Phase 4
26 Peripheral Nervous System Agents Phase 4,Phase 3
27 Analgesics Phase 4
28 Analgesics, Non-Narcotic Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Antipyretics Phase 4
32 Antirheumatic Agents Phase 4
33 Cyclooxygenase Inhibitors Phase 4
34 Fibrinolytic Agents Phase 4
35 Platelet Aggregation Inhibitors Phase 4
36
Coumarin Experimental, Nutraceutical Phase 4 91-64-5 323
37
Bisoprolol Approved Phase 3 66722-44-9 2405
38
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
39
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
40
Coal tar Approved Phase 3 8007-45-2
41 Melarsoprol Investigational Phase 3 494-79-1
42 Adrenergic beta-1 Receptor Antagonists Phase 3
43 Autonomic Agents Phase 3
44 Sympatholytics Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
46 Antioxidants Phase 3
47 Micronutrients Phase 3
48 Protective Agents Phase 3
49 Sodium Selenite Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 75)

# Name Status NCT ID Phase Drugs
1 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Unknown status NCT01678599 Phase 4 Benznidazole
2 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Unknown status NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
3 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
4 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
5 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
6 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
7 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
8 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4 Aspirin
9 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
10 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
11 Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
12 Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
13 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
14 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
15 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
16 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
17 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
18 Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
19 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
20 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
21 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
22 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
23 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Active, not recruiting NCT02169557 Phase 2, Phase 3 Fexinidazole
24 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Active, not recruiting NCT02184689 Phase 2, Phase 3 fexinidazole
25 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
26 Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
27 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
28 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
29 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
30 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
31 Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
32 A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
33 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
34 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
35 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
36 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
37 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
38 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole Completed NCT00982904 Phase 1 Fexinidazole/Placebo
39 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Completed NCT01533961 Phase 1 SCYX-7158;Placebo
40 Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation Completed NCT02571062 Phase 1 Fexinidazole
41 Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions Completed NCT01340157 Phase 1 Fexinidazole
42 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
43 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
44 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Not yet recruiting NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
45 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
46 Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
47 Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram Unknown status NCT00453700
48 Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Unknown status NCT02295215
49 Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Unknown status NCT02099903
50 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) Completed NCT01766830

Search NIH Clinical Center for Trypanosomiasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: trypanosomiasis

Genetic Tests for Trypanosomiasis

Anatomical Context for Trypanosomiasis

MalaCards organs/tissues related to Trypanosomiasis:

38
Testes, Heart, Brain, T Cells, B Cells, Endothelial, Myeloid

Publications for Trypanosomiasis

Articles related to Trypanosomiasis:

(show top 50) (show all 661)
# Title Authors Year
1
Oral fexinidazole for human African trypanosomiasis. ( 29353603 )
2018
2
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT). ( 29169674 )
2018
3
Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017. ( 29350158 )
2018
4
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. ( 29113731 )
2018
5
A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo. ( 29246478 )
2018
6
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. ( 29191556 )
2018
7
Trypanosomiasis in a Young Infant from Rural Gujarat, India. ( 29396940 )
2018
8
The structure of serum resistance-associated protein and its implications for human African trypanosomiasis. ( 29358741 )
2018
9
Candidate genes-based investigation of susceptibility to Human African Trypanosomiasis in CA'te d'Ivoire. ( 29059176 )
2017
10
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. ( 28552771 )
2017
11
An overlooked horticultural crop, Smyrnium olusatrum, as a potential source of compounds effective against African trypanosomiasis. ( 28087440 )
2017
12
Vertical transmission of human African trypanosomiasis: Clinical evolution and brain MRI of a mother and her son. ( 28750004 )
2017
13
The socio-economic burden of human African trypanosomiasis and the coping strategies of households in the South Western Kenya foci. ( 29073144 )
2017
14
The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question. ( 28957467 )
2017
15
Discovery and genomic analyses of hybridization between divergent lineages of Trypanosoma congolense, causative agent of Animal African Trypanosomiasis. ( 28752916 )
2017
16
Impact of the Ebola outbreak on Trypanosoma brucei gambiense infection medical activities in coastal Guinea, 2014-2015: A retrospective analysis from the Guinean national Human African Trypanosomiasis control program. ( 29131822 )
2017
17
Case of Nigeria-Acquired Human African Trypanosomiasis in United Kingdom, 2016. ( 28628444 )
2017
18
African animal trypanosomiasis as a constraint to livestock health and production in Karamoja region: a detailed qualitative and quantitative assessment. ( 29178951 )
2017
19
Chagas Disease (American Trypanosomiasis) ( 29083573 )
2017
20
The study of trypanosome species circulating in domestic animals in two human African trypanosomiasis foci of CA'te d'Ivoire identifies pigs and cattle as potential reservoirs of Trypanosoma brucei gambiense. ( 29045405 )
2017
21
Inhibitors of glycosomal protein import provide new leads against trypanosomiasis. ( 28706938 )
2017
22
Hsp70/J-protein machinery from Glossina morsitans morsitans, vector of African trypanosomiasis. ( 28902917 )
2017
23
Serological tests for gambiense human African trypanosomiasis detect antibodies in cattle. ( 29100526 )
2017
24
Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier dysfunction in an experimental murine model of human African trypanosomiasis. ( 28636879 )
2017
25
Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. ( 28827791 )
2017
26
Expression of interferon-inducible chemokines and sleep/wake changes during early encephalitis in experimental African trypanosomiasis. ( 28821016 )
2017
27
People, Patches, and Parasites: The Case of Trypanosomiasis in Zimbabwe. ( 29170590 )
2017
28
Sexual transmission of American trypanosomiasis in humans: a new potential pandemic route for Chagas parasites. ( 28591404 )
2017
29
Performance of the SD BIOLINEAr HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo. ( 28672036 )
2017
30
Monitoring the elimination of human African trypanosomiasis: Update to 2014. ( 28531222 )
2017
31
Human African trypanosomiasis. ( 28673422 )
2017
32
Enhanced passive screening and diagnosis for gambiense human African trypanosomiasis in north-western Uganda - Moving towards elimination. ( 29023573 )
2017
33
Introducing the TrypanoGEN biobank: A valuable resource for the elimination of human African trypanosomiasis. ( 28570558 )
2017
34
Erratum: Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis. ( 28074881 )
2017
35
Animal African Trypanosomiasis in Nigeria: A long way from elimination/eradication. ( 28870536 )
2017
36
Bovine trypanosomiasis in tsetse-free pastoral zone of the Far-North region, Cameroon. ( 29097642 )
2017
37
African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase. ( 29107420 )
2017
38
Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis. ( 28713367 )
2017
39
Trypanosomiasis in an Australian little red flying fox (Pteropus scapulatus). ( 28653380 )
2017
40
Use of Zymography in Trypanosomiasis Studies. ( 28608214 )
2017
41
Human African trypanosomiasis control: Achievements and challenges. ( 28426685 )
2017
42
APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. ( 28537557 )
2017
43
Pastoralists' Vulnerability to Trypanosomiasis in Maasai Steppe. ( 29098491 )
2017
44
Human African Trypanosomiasis in the Kafue National Park, Zambia. ( 27196336 )
2016
45
Host Intracellular Signaling Events and Pro-inflammatory Cytokine Production in African Trypanosomiasis. ( 27242788 )
2016
46
Revisiting zoonotic human African trypanosomiasis control in Uganda. ( 26779716 )
2016
47
Human African trypanosomiasis diagnosis by peripheral blood smear review in a Spanish traveler. ( 27127825 )
2016
48
Assessment of animal African trypanosomiasis (AAT) vulnerability in cattle-owning communities of sub-Saharan Africa. ( 26825496 )
2016
49
The Inhibition of Cysteine Proteases Rhodesain and TbCatB: a Valuable Approach to Treat Human African Trypanosomiasis. ( 27156518 )
2016
50
Human Trypanosomiasis in the Eastern Plains of Colombia: New Transmission Scenario. ( 26728765 )
2016

Variations for Trypanosomiasis

Expression for Trypanosomiasis

Search GEO for disease gene expression data for Trypanosomiasis.

Pathways for Trypanosomiasis

Pathways related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 CALR CCL2 CCL3 CXCL8 HP IFNG
2
Show member pathways
13.77 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
3
Show member pathways
13.66 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
4
Show member pathways
13.55 CCL2 CCL3 CXCL8 IL10 IL1B IL2
5
Show member pathways
13.5 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
6
Show member pathways
13.43 CCL2 CCL3 CXCL8 IL10 IL1B IL2
7
Show member pathways
13.05 CCL2 CXCL8 IL1B IL6 TLR9 TNF
8
Show member pathways
13 CALR CXCL8 IFNG IL10 IL1B IL2
9
Show member pathways
12.94 CCL2 CXCL8 IFNG IL1B IL2 IL4
10
Show member pathways
12.79 CXCL8 IFNG IL1B IL6 TNF
11
Show member pathways
12.77 IL1B IL2 IL6 TLR9 TNF
12
Show member pathways
12.76 IFNG IL10 IL1B IL2 IL4 IL6
13
Show member pathways
12.75 CCL2 IFNG IL10 IL1B IL2 IL6
14
Show member pathways
12.7 IFNG IL10 IL2 IL4 TNF
15 12.7 CCL2 IDO1 IFNG IL10 IL1B IL2
16
Show member pathways
12.6 IFNG IL10 IL1B IL2 IL4 IL6
17
Show member pathways
12.5 IFNG IL10 IL2 IL4 IL6
18
Show member pathways
12.5 CCL2 CXCL8 IFNG IL1B IL4 IL6
19
Show member pathways
12.49 ALB CCL2 IFNG IL1B IL2 IL4
20
Show member pathways
12.49 CALR CCL2 CCL3 CXCL8 IFNG IL10
21
Show member pathways
12.41 CXCL8 IFNG IL1B IL6 TNF
22
Show member pathways
12.39 IFNG IL10 IL1B IL4 TNF
23 12.39 IFNG IL10 IL1B IL6 TLR9 TNF
24 12.34 CXCL8 IL10 IL1B IL6 TF TNF
25
Show member pathways
12.34 CXCL8 IFNG IL1B IL4 IL6 TLR9
26
Show member pathways
12.33 CXCL8 IL6 TLR9 TNF
27
Show member pathways
12.27 CXCL8 IFNG IL10 IL1B IL2 IL4
28 12.26 IFNG IL6 TLR9 TNF
29 12.18 CCL2 IFNG IL1B TNF
30 12.17 IFNG IL10 IL2 IL4 IL6 TNF
31
Show member pathways
12.15 CCL3 IFNG IL1B IL2 IL4
32 12.15 CCL2 CXCL8 IL10 IL1B IL4 IL6
33 12.12 CCL3 CXCL8 IFNG IL1B IL6
34
Show member pathways
12.11 ALB APOL1 CALR HP HPR
35
Show member pathways
12.09 IFNG IL10 IL1B IL2 IL6 TLR9
36 12.09 CCL2 CXCL8 IFNG IL1B IL2 IL4
37 12.08 CCL2 CXCL8 IL1B IL6 TNF
38 12.07 CCL2 IL1B IL6 TNF
39 12.07 CXCL8 IFNG IL10 IL1B IL6 TNF
40
Show member pathways
12.04 IFNG IL1B IL4 IL6 TLR9
41 12.01 IL1B IL4 IL6 TNF
42 12.01 CCL3 CXCL8 IFNG IL1B IL6
43 12.01 CCL2 CCL3 CXCL8 IFNG IL1B IL6
44 11.98 CXCL8 IFNG IL2 IL4 IL6
45 11.95 IFNG IL10 IL2 IL6
46
Show member pathways
11.94 CXCL8 IFNG IL2 IL4 TNF
47 11.94 CCL3 IFNG IL10 IL1B IL2 IL4
48 11.93 CXCL8 IL10 IL1B IL6 TNF
49 11.89 IFNG IL10 IL1B IL2 IL6 TLR9
50 11.86 IL10 IL4 IL6 TLR9 TNF

GO Terms for Trypanosomiasis

Cellular components related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 ALB APOL1 CALR CCL2 CCL3 CXCL8
2 endoplasmic reticulum lumen GO:0005788 9.65 ALB APOL1 CALR IL6 TF
3 blood microparticle GO:0072562 9.55 ALB APOL1 HP HPR TF
4 extracellular space GO:0005615 9.53 ALB APOL1 CALR CCL2 CCL3 CXCL8

Biological processes related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.98 IFNG IL1B IL2 TNF
2 chemotaxis GO:0006935 9.97 CCL2 CCL3 CXCL8 IL4
3 receptor-mediated endocytosis GO:0006898 9.97 ALB APOL1 CALR HP HPR
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 IL1B IL6 TLR9 TNF
5 positive regulation of DNA binding transcription factor activity GO:0051091 9.92 IL10 IL1B IL6 TNF
6 positive regulation of gene expression GO:0010628 9.91 CALR CCL3 IFNG IL1B IL6 TLR9
7 cellular response to interleukin-1 GO:0071347 9.9 CCL2 CCL3 CXCL8
8 chemokine-mediated signaling pathway GO:0070098 9.9 CCL2 CCL3 CXCL8
9 positive regulation of JNK cascade GO:0046330 9.9 IL1B TLR9 TNF
10 regulation of insulin secretion GO:0050796 9.89 IFNG IL1B TNF
11 positive regulation of inflammatory response GO:0050729 9.88 CCL3 IL2 TLR9
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IFNG IL2 IL6
13 response to glucocorticoid GO:0051384 9.88 IL10 IL6 TNF
14 cellular response to organic cyclic compound GO:0071407 9.86 CCL2 CCL3 IL1B TNF
15 positive regulation of interferon-gamma production GO:0032729 9.84 IL1B IL2 TNF
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IFNG IL1B TNF
17 neutrophil chemotaxis GO:0030593 9.84 CCL2 CCL3 CXCL8 IL1B
18 monocyte chemotaxis GO:0002548 9.83 CCL2 CCL3 IL6
19 positive regulation of B cell proliferation GO:0030890 9.83 IL2 IL4 TLR9
20 positive regulation of T cell proliferation GO:0042102 9.83 IL1B IL2 IL4 IL6
21 inflammatory response GO:0006954 9.81 CCL2 CCL3 CXCL8 IDO1 IL10 IL1B
22 positive regulation of phagocytosis GO:0050766 9.8 CALR IL1B TNF
23 humoral immune response GO:0006959 9.8 CCL2 IFNG IL6 TNF
24 cellular response to lipopolysaccharide GO:0071222 9.8 CCL2 CXCL8 IL10 IL6 TNF
25 positive regulation of interleukin-8 production GO:0032757 9.79 IL1B TLR9 TNF
26 negative regulation of interleukin-6 production GO:0032715 9.78 IL10 TLR9 TNF
27 positive regulation of interleukin-12 production GO:0032735 9.77 IDO1 IFNG TLR9
28 positive regulation of NF-kappaB import into nucleus GO:0042346 9.76 IL1B TLR9 TNF
29 positive regulation of interleukin-6 production GO:0032755 9.76 IL1B IL6 TLR9 TNF
30 positive regulation of chemokine production GO:0032722 9.75 IL6 TLR9 TNF
31 polyamine biosynthetic process GO:0006596 9.73 AMD1 ODC1
32 PERK-mediated unfolded protein response GO:0036499 9.73 CCL2 CXCL8
33 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL2 IL6
34 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL1B TLR9
35 protein kinase B signaling GO:0043491 9.73 CCL2 CCL3 IL1B TNF
36 negative regulation of lipid storage GO:0010888 9.72 IL6 TNF
37 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 IFNG IL1B TNF
38 polyamine metabolic process GO:0006595 9.71 AMD1 ODC1
39 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL2 IL4
40 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TNF
41 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
42 regulation of establishment of endothelial barrier GO:1903140 9.69 IL1B TNF
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL10 IL4
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.69 IL10 TNF
45 response to molecule of bacterial origin GO:0002237 9.69 CXCL8 IL10 TLR9
46 astrocyte cell migration GO:0043615 9.68 CCL2 CCL3
47 type 2 immune response GO:0042092 9.68 IL10 IL4
48 negative regulation of interleukin-8 production GO:0032717 9.68 IL10 TLR9
49 positive regulation of fever generation GO:0031622 9.67 IL1B TNF
50 sequestering of triglyceride GO:0030730 9.65 IL1B TNF

Molecular functions related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL10 IL2 IL4 IL6
2 chemokine activity GO:0008009 9.43 CCL2 CCL3 CXCL8
3 cytokine activity GO:0005125 9.32 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
4 hemoglobin binding GO:0030492 8.96 HP HPR

Sources for Trypanosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....